A new patient database launched last night containing clinical trial records from more than 8,500 ALS patients.
The PRO-ACT (Pooled Resource Open-Access ALS Clinical Trials) database was launched by Prize4Life, a nonprofit organization whose mission is to accelerate the discovery of treatments and a cure for ALS (Amyotrophic Lateral Sclerosis, also known as Lou Gehrig’s disease), along with the Neurological Clinical Research Institute (NCRI) at Massachusetts General Hospital. Funding was provided by the ALS Therapy Alliance and in partnership with the Northeast ALS Consortium (NEALS).
The records in the database came from pharmaceutical companies including Sanofi, Novartis, Teva Pharmaceutical Industries, and Regeneron Pharmaceuticals, as well as academic institutions around the world. Records include demographic, lab, medical history, functional scores, and other data elements. The dataset currently includes both placebo and, in most instances, treatment-arm data from 18 late stage (Phase II/III) ALS clinical trials, resulting in over eight million longitudinally collected data points.